Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: PEG-L-asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: mercaptopurine
Drug: ifosfamide
Drug: methotrexate
Drug: vincristine sulfate
Drug: prednisone
Radiation: Radiation Therapy
Drug: thioguanine
Drug: vindesine
Drug: daunoxome
Drug: fludarabine

First Posted Date: 2010-05-05

Last Posted Date: 2022-05-24

Lead Sponsor: University Hospital Schleswig-Holstein

Target Recruit Count: 6136

Registration Number: NCT01117441

Locations: 🇦🇹
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde, Klagenfurt, Austria
🇨🇿
University Hospital Brno, Department of Pediatric Oncology, Brno, Czechia
🇩🇪
Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie, Berlin, Germany

and more 134 locations

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase 2

Completed

Conditions: Nodal Marginal Zone B-cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma

Interventions: Drug: bendamustine hydrochloride
Drug: dexamethasone
Biological: filgrastim
Procedure: leukapheresis
Other: laboratory biomarker analysis
Other: flow cytometry
Drug: etoposide

First Posted Date: 2010-04-26

Last Posted Date: 2017-05-24

Lead Sponsor: University of Washington

Target Recruit Count: 43

Registration Number: NCT01110135

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

Phase 2

Completed

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: ATG, rabbit
Drug: Etoposide
Drug: Methotrexate
Drug: hydrocortisone
Drug: Dexamethasone

First Posted Date: 2010-04-15

Last Posted Date: 2020-10-19

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 31

Registration Number: NCT01104025

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

and more 11 locations

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Biological: Filgrastim
Drug: Ifosfamide
Procedure: Leukapheresis
Drug: Plerixafor
Biological: Rituximab

First Posted Date: 2010-04-01

Last Posted Date: 2018-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01097057

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Phase 3

Active, not recruiting

Conditions: Clear Cell Ependymoma
Papillary Ependymoma
Anaplastic Ependymoma
Cellular Ependymoma
Ependymoma
Brain Ependymoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Other: Clinical Observation
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mesna
Drug: Vincristine

First Posted Date: 2010-03-31

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 479

Registration Number: NCT01096368

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

and more 206 locations

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Leukemia
Oral Complications
Mucositis

Interventions: Biological: rituximab
Biological: palifermin
Drug: cyclophosphamide
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: cytarabine
Drug: daunorubicin hydrochloride
Radiation: total-body irradiation
Drug: etoposide
Drug: fludarabine phosphate
Drug: imatinib mesylate
Drug: melphalan
Drug: mercaptopurine
Drug: methotrexate
Drug: nelarabine
Drug: pegaspargase
Drug: vincristine sulfate

First Posted Date: 2010-03-12

Last Posted Date: 2024-05-10

Lead Sponsor: University College, London

Target Recruit Count: 1033

Registration Number: NCT01085617

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Drug: Testosterone injection
Drug: Etoposide

First Posted Date: 2010-03-10

Last Posted Date: 2016-05-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 16

Registration Number: NCT01084759

Locations: 🇺🇸
Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Radiation: proton beam radiation therapy
Drug: cisplatin
Drug: etoposide
Procedure: therapeutic conventional surgery

First Posted Date: 2010-02-26

Last Posted Date: 2021-05-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 34

Registration Number: NCT01076231

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Drug: DFMO
Drug: Etoposide

First Posted Date: 2010-01-29

Last Posted Date: 2024-08-06

Lead Sponsor: Giselle Sholler

Target Recruit Count: 21

Registration Number: NCT01059071

Locations: 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸
UVM/FAHC, Burlington, Vermont, United States

and more 4 locations

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma
Plasma Cell Myeloma

Interventions: Drug: bortezomib
Drug: cisplatin
Drug: cyclophosphamide
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: lenalidomide
Drug: melphalan
Drug: thalidomide
Genetic: gene expression analysis
Genetic: microarray analysis
Other: laboratory biomarker analysis
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation

First Posted Date: 2010-01-25

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT01055301

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Group Health Central Hospital, Seattle, Washington, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy